Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 5/20 | 0.57 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.57 |
| ▸ | PPARG | P37231 | 2/20 | 0.56 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.56 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.56 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30849959 | 0.91 | AGTR1 (0.53) | AGTR1AGTR2PPARGABCC3ABCC4 | |
| SCHEMBL21083646 | 0.91 | AGTR1 (0.53) | AGTR1AGTR2PPARGABCC3ABCC4 | |
| SCHEMBL2578611 | 0.89 | AGTR1 (0.67) | AGTR1AGTR2PPARG | |
| SCHEMBL1417546 | 0.88 | AGTR1 (0.61) | AGTR1AGTR2PPARG | |
| SCHEMBL12593005 | 0.88 | AGTR2 (0.74) | AGTR1AGTR2PPARGABCC3ABCC4 | |
| SCHEMBL4592079 | 0.87 | PPARG (0.57) | AGTR1AGTR2PPARG | |
| SCHEMBL7310143 | 0.86 | AGTR1 (0.63) | AGTR1AGTR2 | |
| SCHEMBL12737295 | 0.85 | PPARG (0.64) | AGTR1AGTR2PPARG | |
| SCHEMBL7309439 | 0.85 | PPARG (0.60) | AGTR1AGTR2PPARGABCC3ABCC4 | |
| Hydrochloric Acid SCHEMBL7303166 | 0.85 | AGTR1 (0.62) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2298763-B1 | METHOD FOR PRODUCING 1-BIPHENYLMETHYLIMIDAZOLE COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2015-03-25 | — | — | EP | disclosed |
| EP-2298763-B1 | METHOD FOR PRODUCING 1-BIPHENYLMETHYLIMIDAZOLE COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2015-03-25 | — | — | EP | disclosed |
| US-8735598-B2 | Method for producing 1-biphenylmethylimidazole compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-27 | — | — | US | disclosed |
| US-8735598-B2 | Method for producing 1-biphenylmethylimidazole compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-27 | — | — | US | disclosed |
| US-8735598-B2 | Method for producing 1-biphenylmethylimidazole compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-27 | — | — | US | disclosed |
| WO-2012148148-A9 | NOVEL ZINC AZIDE COMPLEX AND A PROCESS FOR PREPARING TETRAZOLE DERIVATIVES USING THE SAME | LG LIFE SCIENCES LTD. (KR) | 2013-02-14 | — | — | WO | disclosed |
| WO-2012148148-A2 | NOVEL ZINC AZIDE COMPLEX AND A PROCESS FOR PREPARING TETRAZOLE DERIVATIVES USING THE SAME | LG LIFE SCIENCES LTD. (KR) | 2012-11-01 | — | — | WO | disclosed |
| US-7943779-B2 | Process for the preparation of olmesartan medoxomil | KRKA (SI) | 2011-05-17 | — | — | US | disclosed |
| US-20110092713-A1 | METHOD FOR PRODUCING 1-BIPHENYLMETHYLIMIDAZOLE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-21 | — | — | US | disclosed |
| US-20110092713-A1 | METHOD FOR PRODUCING 1-BIPHENYLMETHYLIMIDAZOLE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-21 | — | — | US | disclosed |
| US-20080312451-A1 | Process For the Preparation of Sartan Derivatives and Intermediates Useful in Such Process | KRKA, D.D. NOVO MESTO (SK) | 2008-12-18 | — | — | US | disclosed |
| EP-1931655-A2 | A PROCESS FOR THE PREPARATION OF SARTAN DERIVATIVES AND INTERMEDIATES USEFUL IN SUCH PROCESS | KRKA, D.D., Novo Mesto (SI) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007039117-A2 | A PROCESS FOR THE PREPARATION OF SARTAN DERIVATIVES AND INTERMEDIATES USEFUL IN SUCH PROCESS | KRKA, D.D., NOVO, MESTO (SI) | 2007-04-12 | — | — | WO | disclosed |
| US-20070054948-A1 | Purification of olmesartan medoxomil | TEVA PHARMACEUTICALS USA, INC. | 2007-03-08 | — | — | US | disclosed |
| WO-2006029056-A1 | PREPARATION OF OLMESARTAN MEDOXOMIL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006029057-A1 | PURIFICATION OF OLMESARTAN MEDOXOMIL | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2006-03-16 | — | — | WO | disclosed |
| EP-0503785-B1 | 1-Biphenylimidazole derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 2001-04-25 | — | — | EP | disclosed |
| US-5646171-A | HYPOTENSIVE AGENTS | SANKYO COMPANY, LIMITED (JP) | 1997-07-08 | — | — | US | disclosed |
| US-5616599-A | HYPOTENSIVE AGENTS FOR CARDIOVASCULAR DISORDER | SANKYO COMPANY, LIMITED (JP) | 1997-04-01 | — | — | US | disclosed |
| EP-0503785-A1 | 1-Biphenylimidazole derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1992-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054948-A1 | Purification of olmesartan medoxomil | AGTR2, AGTR1, REN | AGTR1 2/4885AGTR2 1/4885PPARG 2117/4885 |
| US-20080312451-A1 | Process For the Preparation of Sartan Derivatives and Intermediates Useful in Such Process | MC5R, NPY5R, ADRA1D | AGTR1 283/4885AGTR2 311/4885PPARG 3411/4885 |
| US-20110092713-A1 | METHOD FOR PRODUCING 1-BIPHENYLMETHYLIMIDAZOLE COMPOUND | AGTR1, AGTR2, AOC3 | AGTR1 1/4885AGTR2 2/4885PPARG 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.